Health economics in drug development: efficient research to inform healthcare funding decisions.
In order to decide whether a new treatment should be used in patients, a robust estimate of efficacy and toxicity is no longer sufficient. As a result of increasing healthcare costs across the globe healthcare payers and providers now seek estimates of cost-effectiveness as well. Most trials currently being designed still only consider the need for prospective efficacy and toxicity data during the development life-cycle of a new intervention. Hence the cost-effectiveness estimates are inevitably less precise than the clinical data on which they are based. Methods based on decision theory are being developed by health economists that can contribute to the design of clinical trials in such a way that they can more effectively lead to better informed drug funding decisions on the basis of cost-effectiveness in addition to clinical outcomes. There is an opportunity to apply these techniques prospectively in the design of future clinical trials. This article describes the problems encountered by those responsible for drug reimbursement decisions as a consequence of the current drug development pathway. The potential for decision theoretic methods to help overcome these problems is introduced and potential obstacles in implementation are highlighted.
Hall
Peter S
PS
University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds LS2 9LJ, UK. p.s.hall@leeds.ac.uk
McCabe
Christopher
C
Brown
Julia M
JM
Cameron
David A
DA
D035843:Biomedical Research / Q000191:economics*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003657:Decision Making; D003661:Decision Support Techniques; D003695:Delivery of Health Care / Q000191:economics*; D005381:Financing, Organized; D006801:Humans; D012107:Research Design; D013678:Technology, Pharmaceutical / Q000191:economics*